VXc-486

Research use only, not for human use.

VXc-486 (VXc486) is a novel inhibitor of gyrase B, potently inhibits multiple drug-sensitive isolates and drug-resistant isolates of Mycobacterium tuberculosis in vitro.

VXc-486 (VXc486) is a novel inhibitor of gyrase B, potently inhibits multiple drug-sensitive isolates and drug-resistant isolates of Mycobacterium tuberculosis in vitro with MICs of 0.03-0.30 μg/ml and 0.08-5.48 μg/ml, respectively; VXc-486 is active against drug-resistant isolates, has bactericidal activity, and kills intracellular and dormant M. tuberculosis bacteria in a low-oxygen environment; inhibits the growth of multiple strains of Mycobacterium abscessus, Mycobacterium avium complex, and Mycobacterium kansasii (MICs=0.1-2.0 μg/ml), as well as several strains of Nocardia spp. (MICs=0.1-1.0 μg/ml); reduces mycobacterial burdens in lungs of infected mice in vivo, sterilizes M. tuberculosis infection when combined with rifapentine-pyrazinamide and bedaquiline-pyrazinamide.

——

——

VXc486

GPCR/G Protein

Antibacterial

Antibacterial

——

——

1384984-18-2

428.468

C21H25FN6O3

>98% (HPLC)

In Vitro:?DMSO : 20 mg/mL (46.68 mM)

CCNC(=O)NC1=NC2=C(N1)C=C(C(=C2C3CCCO3)F)C4=CN=C(N=C4)C(C)(C)O

N-Ethyl-N'-[6-fluoro-5-[2-(1-hydroxy-1-methylethyl)-5-pyrimidinyl]-7-[(2R)-tetrahydro-2-furanyl]-1H-benzimidazol-2-yl]urea

(-20℃)

With Ice Pack

≥ 2 years